Biofidelity announces first peer reviewed publication of breakthrough ASPYRE technology
- Date 29 Mar 2021
Biofidelity Ltd, the cancer diagnostics company, today announces that the first peer review article detailing its novel ASPYRE technology has been published in Scientific Reports, a Nature journal. The article, titled "Single-copy detection of somatic variants from solid and liquid biopsy" is freely available online at www.nature.com/articles/s41598-021-85545-3.
As well as detailing the novel technology behind ASPYRE, the publication evidences the flexibility of Biofidelity’s breakthrough approach, through its application to the detection of a variety of key genetic mutations used to guide treatment decisions in lung cancer.
You might also be interested in these articles
Technology
Answer the call for speakers & start-ups for CW's International Conference
None
Thu 7 Nov 2024
CW (Cambridge Wireless Ltd)
Technology
Celebrating the Cambridge Tech Week Innovation Alley Award Winners
None
Wed 2 Oct 2024
CW (Cambridge Wireless Ltd)
Technology
Optalysys wins the Business Weekly and Cambridge Tech Week Scale-Up Business Plan Competition
None
Wed 2 Oct 2024
CW (Cambridge Wireless Ltd)